ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
